ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Experimental: Participant Group CHF 5993 pMDI HFA-152a

Its studies are mostly in Asthma, led by Chiesi Farmaceutici.

Furthest: phase 3, since Mar 30, 20261 company-led study, 1 open or runningNext primary completion: Oct 17, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chiesi Farmaceutici11 open or runningphase 3since Mar 30, 2026Mar 30, 2026Oct 17, 2028phase 3 · NCT07546981

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 30, 2026First study: phase 3 study in AsthmaFirst studyNCT07546981 · 554 planned · China

Ahead

  1. Oct 17, 2028Primary completion: phase 3 study in AsthmaNCT07546981

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07546981Asthma · China3RecruitingOct 17, 2028554

How it is read

Names in the registry

  • “Experimental: Participant Group CHF 5993 pMDI HFA-152a”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.